CL2020002695A1 - Péptidos macrocíclicos contra actinetobacter baumannii - Google Patents

Péptidos macrocíclicos contra actinetobacter baumannii

Info

Publication number
CL2020002695A1
CL2020002695A1 CL2020002695A CL2020002695A CL2020002695A1 CL 2020002695 A1 CL2020002695 A1 CL 2020002695A1 CL 2020002695 A CL2020002695 A CL 2020002695A CL 2020002695 A CL2020002695 A CL 2020002695A CL 2020002695 A1 CL2020002695 A1 CL 2020002695A1
Authority
CL
Chile
Prior art keywords
actinetobacter
baumannii
macrocyclic peptides
peptides against
formula
Prior art date
Application number
CL2020002695A
Other languages
English (en)
Inventor
Theodor Stoll
taishan Hu
Patrizio Mattei
Giorgio Patrick Di
Petra Schmitz
Konrad Bleicher
Daniella Cheang
Christian Jenny
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2020002695A1 publication Critical patent/CL2020002695A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona compuestos de fórmula (I); en la que X1, X2, R1 a R6 y A son tal como se indica en la presente memoria, así como sales farmacéuticamente aceptables de los<br /> mismos. Además, la presente invención se refiere a la preparación de los compuestos de fórmula (I), composiciones farmacéuticas que los comprenden y a su utilización como medicamentos destinados al tratamiento de enfermedades e infecciones causadas por bacterias.
CL2020002695A 2018-04-23 2020-10-16 Péptidos macrocíclicos contra actinetobacter baumannii CL2020002695A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/084131 2018-04-23

Publications (1)

Publication Number Publication Date
CL2020002695A1 true CL2020002695A1 (es) 2021-02-19

Family

ID=66290410

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002695A CL2020002695A1 (es) 2018-04-23 2020-10-16 Péptidos macrocíclicos contra actinetobacter baumannii

Country Status (20)

Country Link
US (2) US11819532B2 (es)
EP (1) EP3784262A1 (es)
JP (3) JP7460541B2 (es)
KR (1) KR102855963B1 (es)
CN (1) CN111886020B (es)
AR (1) AR114290A1 (es)
AU (1) AU2019260124B2 (es)
BR (1) BR112020021729A2 (es)
CA (1) CA3089688A1 (es)
CL (1) CL2020002695A1 (es)
CR (1) CR20200488A (es)
IL (2) IL309537A (es)
MA (1) MA52352A (es)
MX (1) MX2020007633A (es)
PE (1) PE20210855A1 (es)
PH (1) PH12020551762A1 (es)
SG (1) SG11202007219PA (es)
TW (1) TWI833748B (es)
UA (1) UA126943C2 (es)
WO (1) WO2019206853A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016347456B2 (en) 2015-10-27 2018-12-13 F. Hoffmann-La Roche Ag Peptide macrocycles against acinetobacter baumannii
US11505573B2 (en) 2018-03-28 2022-11-22 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
FI3784663T3 (fi) 2018-04-23 2023-10-06 Celgene Corp Substituoituja 4-aminoisoindoliini-1,3-dioniyhdisteitä ja niiden käyttö lymfooman hoitamiseksi
US11819532B2 (en) * 2018-04-23 2023-11-21 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
WO2020182648A1 (en) 2019-03-08 2020-09-17 F. Hoffmann-La Roche Ag Novel imidazole-pyrazole derivatives
CN114981259B (zh) 2020-01-22 2024-06-18 豪夫迈·罗氏有限公司 新型杂环化合物
JP7771084B2 (ja) 2020-04-29 2025-11-17 エフ． ホフマン－ラ ロシュ アーゲー 抗菌８－フェニルアミノ－３－（ピラゾール－４－イル）イミダゾ［１，２－ａ］ピラジン誘導体
WO2021244997A1 (en) 2020-06-01 2021-12-09 F. Hoffmann-La Roche Ag Novel imidazopyrazne derivatives
WO2021249893A1 (en) 2020-06-08 2021-12-16 F. Hoffmann-La Roche Ag Novel imidazo-pyrazine derivatives
CN115916784A (zh) 2020-06-09 2023-04-04 豪夫迈·罗氏有限公司 新型咪唑并吡嗪衍生物
EP4204090A1 (en) 2020-08-31 2023-07-05 F. Hoffmann-La Roche AG Imidazole-pyrazole derivatives as antibacterials
CN115989227A (zh) 2020-09-01 2023-04-18 豪夫迈·罗氏有限公司 具有抗菌性的咪唑-吡唑衍生物
EP4211116B1 (en) 2020-09-07 2024-08-07 F. Hoffmann-La Roche AG Novel heterocyclic antibiotics
JP2024506021A (ja) 2021-02-07 2024-02-08 エフ． ホフマン－ラ ロシュ アーゲー 新規ヘテロアリール置換イミダゾール誘導体
CN117715892A (zh) 2021-07-06 2024-03-15 豪夫迈·罗氏有限公司 用于治疗细菌感染的季铵阳离子取代化合物
JP2024525793A (ja) 2021-07-15 2024-07-12 エフ． ホフマン－ラ ロシュ アーゲー イミダゾール誘導体及びその抗生物質としての使用
WO2023152347A1 (en) * 2022-02-14 2023-08-17 F. Hoffmann-La Roche Ag Process for manufacturing macrocyclic peptides
JP2025508473A (ja) 2022-02-25 2025-03-26 エフ． ホフマン－ラ ロシュ アーゲー 両性イオン性抗菌化合物
IL315686A (en) 2022-04-07 2024-11-01 Hoffmann La Roche Crystalline forms of macrocyclic peptide antibiotics
JP2025526023A (ja) 2022-08-09 2025-08-07 エフ． ホフマン－ラ ロシュ アーゲー 抗菌性大環状ペプチドの製造プロセス
CN119708122A (zh) * 2023-09-27 2025-03-28 武汉人福创新药物研发中心有限公司 抗鲍曼不动杆菌的环肽及其应用
CN120424159A (zh) * 2024-02-02 2025-08-05 武汉人福创新药物研发中心有限公司 抗鲍曼不动杆菌的含羧酸取代的环肽及其应用
CN118932710A (zh) * 2024-07-01 2024-11-12 宿迁逸达新材料有限公司 一种抗菌涤纶面料的制备方法
WO2026022282A1 (en) 2024-07-26 2026-01-29 F. Hoffmann-La Roche Ag Processes for manufacturing biaryl thioethers
WO2026068674A1 (en) * 2024-09-27 2026-04-02 F. Hoffmann-La Roche Ag Process for deprotection of aminoacid derivatives

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660832B1 (en) 1999-08-20 2003-12-09 Isis Pharmaceuticals, Inc. Macrocyclic compounds and preparation methods thereof
DE10226921A1 (de) 2002-06-17 2003-12-24 Bayer Ag Antibakterielle Amid-Makrozyklen
DE10234422A1 (de) 2002-07-29 2004-02-12 Bayer Ag Antibakterielle Ester-Makrozyklen
EP2186811A1 (en) 2002-08-23 2010-05-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US7491695B2 (en) 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
DK1633774T3 (da) 2003-06-18 2010-05-25 Tranzyme Pharma Inc Makrocykliske motilinreceptorantagonister
EP1498422A1 (de) 2003-07-17 2005-01-19 Jerini AG C5a-Rezeptor-Antagonisten
AU2004261329B2 (en) 2003-07-31 2011-10-27 Ocera Therapeutics, Inc. Spatially-defined macrocyclic compounds useful for drug discovery
CA2533820C (en) 2003-07-31 2016-12-13 Tranzyme Pharma Spatially-defined macrocycles incorporating peptide bond surrogates
WO2005033129A1 (de) 2003-10-01 2005-04-14 Bayer Healthcare Ag Antibakterielle amid-makrozyklen
WO2005090388A1 (en) 2004-03-19 2005-09-29 The University Of Queensland Alpha helical mimics, their uses and methods for their production
DE102004025731A1 (de) 2004-05-26 2005-12-15 Bayer Healthcare Ag Antibakterielle Amid-Makrozyklen III
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
RU2007131267A (ru) 2005-01-17 2009-02-27 Йерини Аг (De) АНТАГОНИСТЫ РЕЦЕПТОРА С5a
DE102005014245A1 (de) 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Antibakterielle Amid-Makrozyklen V
GB0609492D0 (en) * 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
BRPI0807087A2 (pt) 2007-02-08 2014-06-10 Tibotec Pharm Ltd Inibidores de hcv macrocíclicos substituídos de pirimidina
DE112009000300T5 (de) 2008-02-08 2011-01-20 Aileron Therapeutics, Inc., Cambridge Therapeutische Peptidomimetische Makrocyclen
US8338565B2 (en) 2008-08-20 2012-12-25 Ensemble Therapeutics Corporation Macrocyclic compounds for inhibition of tumor necrosis factor alpha
JP2013508409A (ja) 2009-10-23 2013-03-07 トランザイム・ファーマ，インコーポレイテッド セリンプロテアーゼ酵素の大環状阻害剤
EP2493910A1 (en) 2009-10-30 2012-09-05 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
ES2711526T3 (es) 2010-08-13 2019-05-06 Aileron Therapeutics Inc Macrociclos peptidomiméticos
CN103889437A (zh) 2011-08-31 2014-06-25 纽约大学 硫醚、醚和烷基胺连接的氢键替代物肽模拟物
BR112014020103A2 (pt) 2012-02-15 2018-10-09 Aileron Therapeutics, Inc. macrociclos peptidomiméticos
CN103387601B (zh) 2012-05-11 2017-01-11 南开大学 抗登革热病毒(denv)杂环肽类化合物及其制备方法和用途
WO2014048976A1 (en) * 2012-09-25 2014-04-03 Vaxdyn Sl Anti-acinetobacter baumannii immunogens
KR20150088292A (ko) 2012-11-21 2015-07-31 알큐엑스 파마슈티컬스, 인크. 광범위한 마크로사이클릭 항생제
WO2014110420A1 (en) 2013-01-10 2014-07-17 Noliva Therapeutics Llc Peptidomimetic compounds
EP2942389A1 (en) * 2014-05-05 2015-11-11 Servicio Andaluz De Salud Vaccine against Acinetobacter baumannii based on lipopolysaccharide-deficient cellular components
PT3174852T (pt) 2014-07-30 2018-10-23 Abac Therapeutics S L Aril-hidrazidas contendo uma unidade 2-piridona como agentes antibacterianos seletivos
AU2016347456B2 (en) 2015-10-27 2018-12-13 F. Hoffmann-La Roche Ag Peptide macrocycles against acinetobacter baumannii
EP3388444A1 (en) 2017-04-10 2018-10-17 F. Hoffmann-La Roche AG Anti-bacterial peptide macrocycles and use thereof
US11505573B2 (en) 2018-03-28 2022-11-22 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
US11819532B2 (en) 2018-04-23 2023-11-21 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii

Also Published As

Publication number Publication date
CN111886020A (zh) 2020-11-03
WO2019206853A1 (en) 2019-10-31
JP7460541B2 (ja) 2024-04-02
US11819532B2 (en) 2023-11-21
PE20210855A1 (es) 2021-05-18
CA3089688A1 (en) 2019-10-31
US20190321440A1 (en) 2019-10-24
AR114290A1 (es) 2020-08-12
UA126943C2 (uk) 2023-02-22
TWI833748B (zh) 2024-03-01
JP2024050700A (ja) 2024-04-10
IL278053B1 (en) 2024-01-01
JP2021522210A (ja) 2021-08-30
EP3784262A1 (en) 2021-03-03
BR112020021729A2 (pt) 2021-01-26
MA52352A (fr) 2021-03-03
IL309537A (en) 2024-02-01
KR102855963B1 (ko) 2025-09-05
SG11202007219PA (en) 2020-08-28
IL278053B2 (en) 2024-05-01
TW201945386A (zh) 2019-12-01
AU2019260124B2 (en) 2024-12-12
US20240050516A1 (en) 2024-02-15
CN111886020B (zh) 2024-04-05
MX2020007633A (es) 2020-09-14
CR20200488A (es) 2021-02-26
JP2025148419A (ja) 2025-10-07
PH12020551762A1 (en) 2021-06-14
KR20210005574A (ko) 2021-01-14
IL278053A (en) 2020-11-30
AU2019260124A1 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
CL2020002695A1 (es) Péptidos macrocíclicos contra actinetobacter baumannii
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
DOP2012000243A (es) Compuestos de sililo tricíclicos fusionados y uso de los mismos en la fabricación de medicamentos útiles en el tratamiento de enfermedades virales
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
CO6470847A2 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
ECSP22038478A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
CO6470846A2 (es) Derivados aminobut´ricos sustituidos como inhibidores de neprilisina
UY36465A (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
UY33731A (es) ?derivados de ácido amino-fenil-pentanoico sustituidos como inhibidores de nep?
EA201591027A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
DOP2013000142A (es) Derivados de biciclo[3,2,1]octilamida y sus usos.
DOP2015000169A (es) Compuestos tetracíclicos sustituidos con heterociclo y usos de los mismos para el tratamiento de enfermedades víricas
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
UY39181A (es) COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO
MX2023004955A (es) Compuestos de aminotiazol deuterados como compuestos antiviricos.
CY1115600T1 (el) Πιπεραζινες ως ανθελονοσιακοι παραγοντες
MX2021009584A (es) Nuevos derivados de triterpeno como inhibidores del virus de la inmunodeficiencia humana (vih).
MX2015008036A (es) Compuestos antibacterianos.
BR112018008585A2 (pt) macrociclos peptídicos contra a acinotobacter baumannii
CU20120074A7 (es) Derivados del ácido carbamoil-metil-amino-acético sustituido como inhibidores de nep novedosos